| Antibody resistance of SARS-CoV-2 variants B. 1.351 and B. 1.1. 7 P Wang, MS Nair, L Liu, S Iketani, Y Luo, Y Guo, M Wang, J Yu, B Zhang, ... Nature 593 (7857), 130-135, 2021 | 2326 | 2021 |
| Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 L Liu, S Iketani, Y Guo, JFW Chan, M Wang, L Liu, Y Luo, H Chu, Y Huang, ... Nature 602 (7898), 676-681, 2022 | 1156 | 2022 |
| Antibody evasion properties of SARS-CoV-2 Omicron sublineages S Iketani, L Liu, Y Guo, L Liu, JFW Chan, Y Huang, M Wang, Y Luo, J Yu, ... Nature 604 (7906), 553-556, 2022 | 751 | 2022 |
| Antibody evasion by SARS-CoV-2 Omicron subvariants BA. 2.12. 1, BA. 4 and BA. 5 Q Wang, Y Guo, S Iketani, MS Nair, Z Li, H Mohri, M Wang, J Yu, ... Nature 608 (7923), 603-608, 2022 | 659 | 2022 |
| Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants Q Wang, S Iketani, Z Li, L Liu, Y Guo, Y Huang, AD Bowen, M Liu, ... Cell 186 (2), 279-286. e8, 2023 | 543 | 2023 |
| Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite G Cerutti, Y Guo, T Zhou, J Gorman, M Lee, M Rapp, ER Reddem, J Yu, ... Cell host & microbe 29 (5), 819-833. e7, 2021 | 457 | 2021 |
| Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir S Iketani, H Mohri, B Culbertson, SJ Hong, Y Duan, MI Luck, ... Nature 613 (7944), 558-564, 2023 | 183 | 2023 |
| Antibody lineages with vaccine-induced antigen-binding hotspots develop broad HIV neutralization R Kong, H Duan, Z Sheng, K Xu, P Acharya, X Chen, C Cheng, ... Cell 178 (3), 567-584. e19, 2019 | 104 | 2019 |
| Cryo-EM structure of the SARS-CoV-2 Omicron spike G Cerutti, Y Guo, L Liu, L Liu, Z Zhang, Y Luo, Y Huang, HH Wang, DD Ho, ... Cell reports 38 (9), 2022 | 91 | 2022 |
| De novo variants in congenital diaphragmatic hernia identify MYRF as a new syndrome and reveal genetic overlaps with other developmental disorders H Qi, L Yu, X Zhou, J Wynn, H Zhao, Y Guo, N Zhu, A Kitaygorodsky, ... PLoS genetics 14 (12), e1007822, 2018 | 89 | 2018 |
| In silico identification of anti-cancer compounds and plants from traditional Chinese medicine database SX Dai, WX Li, FF Han, YC Guo, JJ Zheng, JQ Liu, Q Wang, YD Gao, ... Scientific reports 6 (1), 25462, 2016 | 86 | 2016 |
| Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA. 2.75 Q Wang, S Iketani, Z Li, Y Guo, AY Yeh, M Liu, J Yu, Z Sheng, Y Huang, ... Cell host & microbe 30 (11), 1512-1517. e4, 2022 | 75 | 2022 |
| Meta-analysis of Parkinson’s disease and Alzheimer’s disease revealed commonly impaired pathways and dysregulation of NRF2-dependent genes Q Wang, WX Li, SX Dai, YC Guo, FF Han, JJ Zheng, GH Li, JF Huang Journal of Alzheimer's Disease 56 (4), 1525-1539, 2017 | 75 | 2017 |
| cAb-Rep: A Database of Curated Antibody Repertoires for Exploring antibody diversity and Predicting Antibody Prevalence Y Guo, K Chen, PD Kwong, L Shapiro, Z Sheng Frontiers in Immunology 10, 2365, 2019 | 64 | 2019 |
| Antigenicity and receptor affinity of SARS-CoV-2 BA. 2.86 spike Q Wang, Y Guo, L Liu, LT Schwanz, Z Li, MS Nair, J Ho, RM Zhang, ... Nature 624 (7992), 639-644, 2023 | 61 | 2023 |
| Resistance of SARS-CoV-2 omicron subvariant BA. 4.6 to antibody neutralisation Q Wang, Z Li, J Ho, Y Guo, AY Yeh, H Mohri, M Liu, M Wang, J Yu, ... The Lancet Infectious Diseases 22 (12), 1666-1668, 2022 | 61 | 2022 |
| Modular basis for potent SARS-CoV-2 neutralization by a prevalent VH1-2-derived antibody class M Rapp, Y Guo, ER Reddem, J Yu, L Liu, P Wang, G Cerutti, P Katsamba, ... Cell Reports 35 (1), 2021 | 60 | 2021 |
| Rare variant analysis of 4241 pulmonary arterial hypertension cases from an international consortium implicates FBLN2, PDGFD, and rare de novo variants in PAH N Zhu, EM Swietlik, CL Welch, MW Pauciulo, JJ Hagen, X Zhou, Y Guo, ... Genome medicine 13 (1), 1-18, 2021 | 59 | 2021 |
| Structural basis for accommodation of emerging B. 1.351 and B. 1.1. 7 variants by two potent SARS-CoV-2 neutralizing antibodies G Cerutti, M Rapp, Y Guo, F Bahna, J Bimela, ER Reddem, J Yu, P Wang, ... Structure 29 (7), 655-663. e4, 2021 | 59 | 2021 |
| Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain G Cerutti, Y Guo, P Wang, MS Nair, M Wang, Y Huang, J Yu, L Liu, ... Cell reports 37 (5), 2021 | 50 | 2021 |
Lihong LiuColumbia UinversityVerified email at cumc.columbia.edu
